NFO period: 16^th January – 30^th January, 2024

Highlights of the NFO:

• Scheme type – An open ended equity scheme investing in Pharma and Healthcare sector


• Investment objective – The primary objective of the scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.


• Product suitability – The product is suitable for investors who are seeking long term capital appreciation by investing predominantly in equity & equity related instruments of Pharma and Healthcare companies.


• Minimum Application Amount – First investment is Rs. 500/- and in multiple of Rs. 1/- thereafter


• Plan/ Options available – Regular Plan and Direct Plan having Growth Option only.


• Fund Managers – Mr. Ramesh Mantri(For Equity Securities), Mr. Dheeresh Pathak(Assistant Fund Manager), Mr. Piyush Baranwal(For Debt Securities) and Mr. Shariq Merchant(For Overseas Investment)


• Benchmark – S&P BSE Healthcare TRI